Kurin

Executive Summary

Kurin, based in San Diego, has developed the Kurin® Blood Culture Collection Set featuring the integrated Kurin Lock®, which automatically sidelines skin contaminants during blood culture collection. This innovation directly addresses the critical problem of false-positive blood cultures due to skin flora, which can lead to unnecessary antibiotic use, prolonged hospital stays, and increased healthcare costs. The device is already FDA-approved and marketed, with the advantage of requiring no change in clinician practice, thus lowering adoption barriers. Kurin's solution is reshaping best practices in blood culture collection, positioning the company as a key player in infection control and diagnostic accuracy. With a strong value proposition in improving patient outcomes and reducing healthcare expenses, Kurin is well-positioned for growth in the infectious disease diagnostics market.

Upcoming Catalysts (preview)

• Q3 2026Publication of real-world evidence demonstrating contamination reduction and cost savings80% success
• Q4 2026Inclusion in clinical practice guidelines or recommendations from infectious disease societies60% success
• Q2 2026Strategic partnership or distribution agreement with a major hospital network or group purchasing organization70% success